roche s elecsys anti sars cov 2 assay Search Results


immunoassays  (Abbott Laboratories)
86
Abbott Laboratories immunoassays
Immunoassays, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/roche+s+elecsys+anti+sars+cov+2+assay/2+anti+assay+cov+igg+ii+quant+sars/pmc12304058-63-14-18
Average 86 stars, based on 1 article reviews
immunoassays - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier
anti-sars-cov-2 elisa igg/s1  (EUROIMMUN)
90
EUROIMMUN anti-sars-cov-2 elisa igg/s1
Anti Sars Cov 2 Elisa Igg/S1, supplied by EUROIMMUN, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/roche+s+elecsys+anti+sars+cov+2+assay/anti+sars+cov+2+elisa++igg+/pm37818799-405-22-24
Average 90 stars, based on 1 article reviews
anti-sars-cov-2 elisa igg/s1 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
gs-cpass  (GenScript corporation)
90
GenScript corporation gs-cpass
Cohort flow chart. A Cohort of non-vaccinated <t>SARS-CoV-2</t> RT-PCR positive subjects. Two recruitment strategies were used: fifty-one participants, who had a SARS CoV-2 infection in February/March 2020 were recruited in April 2020 together with their household members (KUM-Index-study). Forty-two of them had a positive PCR and additional 9 household members developed SARS CoV-2 specific antibodies. From 21 May till 10 December 2020 another fifty-one SARS-CoV-2 infected individuals were recruited as early as possible after their first positive RT-PCR (Koco19-Immu-Study). B Cohort of vaccinees. Forty-five participants with no history of infection but with two vaccinations were recruited
Gs Cpass, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/roche+s+elecsys+anti+sars+cov+2+assay/cpass+sars+cov+2+neutralization+antibody+detection+kit/pmc10474769-56-33-51
Average 90 stars, based on 1 article reviews
gs-cpass - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
sars cov 2 ag immunoassays  (Fujirebio Inc)
95
Fujirebio Inc sars cov 2 ag immunoassays
Cohort flow chart. A Cohort of non-vaccinated <t>SARS-CoV-2</t> RT-PCR positive subjects. Two recruitment strategies were used: fifty-one participants, who had a SARS CoV-2 infection in February/March 2020 were recruited in April 2020 together with their household members (KUM-Index-study). Forty-two of them had a positive PCR and additional 9 household members developed SARS CoV-2 specific antibodies. From 21 May till 10 December 2020 another fifty-one SARS-CoV-2 infected individuals were recruited as early as possible after their first positive RT-PCR (Koco19-Immu-Study). B Cohort of vaccinees. Forty-five participants with no history of infection but with two vaccinations were recruited
Sars Cov 2 Ag Immunoassays, supplied by Fujirebio Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/roche+s+elecsys+anti+sars+cov+2+assay/Lumipulse+G+SARS-CoV-2+Ag/pm37037540-272-34-37
Average 95 stars, based on 1 article reviews
sars cov 2 ag immunoassays - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier
genbody covid-19 igm/igg  (GENBODY Inc)
90
GENBODY Inc genbody covid-19 igm/igg
Cohort flow chart. A Cohort of non-vaccinated <t>SARS-CoV-2</t> RT-PCR positive subjects. Two recruitment strategies were used: fifty-one participants, who had a SARS CoV-2 infection in February/March 2020 were recruited in April 2020 together with their household members (KUM-Index-study). Forty-two of them had a positive PCR and additional 9 household members developed SARS CoV-2 specific antibodies. From 21 May till 10 December 2020 another fifty-one SARS-CoV-2 infected individuals were recruited as early as possible after their first positive RT-PCR (Koco19-Immu-Study). B Cohort of vaccinees. Forty-five participants with no history of infection but with two vaccinations were recruited
Genbody Covid 19 Igm/Igg, supplied by GENBODY Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/roche+s+elecsys+anti+sars+cov+2+assay/genbody+covid+19+ag/pmc07836222-55-6-8
Average 90 stars, based on 1 article reviews
genbody covid-19 igm/igg - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
quest sars-cov-2 rrt-pcr  (LabCorp)
90
LabCorp quest sars-cov-2 rrt-pcr
Cohort flow chart. A Cohort of non-vaccinated <t>SARS-CoV-2</t> RT-PCR positive subjects. Two recruitment strategies were used: fifty-one participants, who had a SARS CoV-2 infection in February/March 2020 were recruited in April 2020 together with their household members (KUM-Index-study). Forty-two of them had a positive PCR and additional 9 household members developed SARS CoV-2 specific antibodies. From 21 May till 10 December 2020 another fifty-one SARS-CoV-2 infected individuals were recruited as early as possible after their first positive RT-PCR (Koco19-Immu-Study). B Cohort of vaccinees. Forty-five participants with no history of infection but with two vaccinations were recruited
Quest Sars Cov 2 Rrt Pcr, supplied by LabCorp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/roche+s+elecsys+anti+sars+cov+2+assay/sars+cov+2+testing/pmc09159971-137-9-18
Average 90 stars, based on 1 article reviews
quest sars-cov-2 rrt-pcr - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
elecsys anti-sars-cov-2 serological assays  (Rochen Pharma Co Ltd)
90
Rochen Pharma Co Ltd elecsys anti-sars-cov-2 serological assays
Cohort flow chart. A Cohort of non-vaccinated <t>SARS-CoV-2</t> RT-PCR positive subjects. Two recruitment strategies were used: fifty-one participants, who had a SARS CoV-2 infection in February/March 2020 were recruited in April 2020 together with their household members (KUM-Index-study). Forty-two of them had a positive PCR and additional 9 household members developed SARS CoV-2 specific antibodies. From 21 May till 10 December 2020 another fifty-one SARS-CoV-2 infected individuals were recruited as early as possible after their first positive RT-PCR (Koco19-Immu-Study). B Cohort of vaccinees. Forty-five participants with no history of infection but with two vaccinations were recruited
Elecsys Anti Sars Cov 2 Serological Assays, supplied by Rochen Pharma Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/roche+s+elecsys+anti+sars+cov+2+assay/rna+fish+probe/pmc09887370__archdischild___2022___324375supp001-17-27-39
Average 90 stars, based on 1 article reviews
elecsys anti-sars-cov-2 serological assays - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
iflash-sars-cov-2  (Shenzhen YHLO)
90
Shenzhen YHLO iflash-sars-cov-2
Cohort flow chart. A Cohort of non-vaccinated <t>SARS-CoV-2</t> RT-PCR positive subjects. Two recruitment strategies were used: fifty-one participants, who had a SARS CoV-2 infection in February/March 2020 were recruited in April 2020 together with their household members (KUM-Index-study). Forty-two of them had a positive PCR and additional 9 household members developed SARS CoV-2 specific antibodies. From 21 May till 10 December 2020 another fifty-one SARS-CoV-2 infected individuals were recruited as early as possible after their first positive RT-PCR (Koco19-Immu-Study). B Cohort of vaccinees. Forty-five participants with no history of infection but with two vaccinations were recruited
Iflash Sars Cov 2, supplied by Shenzhen YHLO, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/roche+s+elecsys+anti+sars+cov+2+assay/iflash+sars+cov+2/pmc09490404-27-30-34
Average 90 stars, based on 1 article reviews
iflash-sars-cov-2 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
enzy-well sars-cov-2 igm, igg, iga  (DIESSE Inc)
90
DIESSE Inc enzy-well sars-cov-2 igm, igg, iga
Cohort flow chart. A Cohort of non-vaccinated <t>SARS-CoV-2</t> RT-PCR positive subjects. Two recruitment strategies were used: fifty-one participants, who had a SARS CoV-2 infection in February/March 2020 were recruited in April 2020 together with their household members (KUM-Index-study). Forty-two of them had a positive PCR and additional 9 household members developed SARS CoV-2 specific antibodies. From 21 May till 10 December 2020 another fifty-one SARS-CoV-2 infected individuals were recruited as early as possible after their first positive RT-PCR (Koco19-Immu-Study). B Cohort of vaccinees. Forty-five participants with no history of infection but with two vaccinations were recruited
Enzy Well Sars Cov 2 Igm, Igg, Iga, supplied by DIESSE Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/roche+s+elecsys+anti+sars+cov+2+assay/enzy+well+sars+cov+2+igg/pm36461032-62-15-16
Average 90 stars, based on 1 article reviews
enzy-well sars-cov-2 igm, igg, iga - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
sars-cov-2 neutralizing ab  (MBL Life science)
90
MBL Life science sars-cov-2 neutralizing ab
Cohort flow chart. A Cohort of non-vaccinated <t>SARS-CoV-2</t> RT-PCR positive subjects. Two recruitment strategies were used: fifty-one participants, who had a SARS CoV-2 infection in February/March 2020 were recruited in April 2020 together with their household members (KUM-Index-study). Forty-two of them had a positive PCR and additional 9 household members developed SARS CoV-2 specific antibodies. From 21 May till 10 December 2020 another fifty-one SARS-CoV-2 infected individuals were recruited as early as possible after their first positive RT-PCR (Koco19-Immu-Study). B Cohort of vaccinees. Forty-five participants with no history of infection but with two vaccinations were recruited
Sars Cov 2 Neutralizing Ab, supplied by MBL Life science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/roche+s+elecsys+anti+sars+cov+2+assay/sars+cov+2+neutralizing+ab+antibody/ppr0466356-146-20-19
Average 90 stars, based on 1 article reviews
sars-cov-2 neutralizing ab - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
sars-cov-2 cov2t  (Siemens AG)
90
Siemens AG sars-cov-2 cov2t
Assay performance for SARS-CoV-2 antibody testing on dried blood spot specimens (DBS).
Sars Cov 2 Cov2t, supplied by Siemens AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/roche+s+elecsys+anti+sars+cov+2+assay/sars+cov+2+total+assay/pmc08651133-212-41-43
Average 90 stars, based on 1 article reviews
sars-cov-2 cov2t - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
sars-cov-2 cov2g  (Siemens AG)
90
Siemens AG sars-cov-2 cov2g
Assay performance for SARS-CoV-2 antibody testing on dried blood spot specimens (DBS).
Sars Cov 2 Cov2g, supplied by Siemens AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/roche+s+elecsys+anti+sars+cov+2+assay/cov2g/pmc08651133-212-17-19
Average 90 stars, based on 1 article reviews
sars-cov-2 cov2g - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Cohort flow chart. A Cohort of non-vaccinated SARS-CoV-2 RT-PCR positive subjects. Two recruitment strategies were used: fifty-one participants, who had a SARS CoV-2 infection in February/March 2020 were recruited in April 2020 together with their household members (KUM-Index-study). Forty-two of them had a positive PCR and additional 9 household members developed SARS CoV-2 specific antibodies. From 21 May till 10 December 2020 another fifty-one SARS-CoV-2 infected individuals were recruited as early as possible after their first positive RT-PCR (Koco19-Immu-Study). B Cohort of vaccinees. Forty-five participants with no history of infection but with two vaccinations were recruited

Journal: Virology Journal

Article Title: Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison

doi: 10.1186/s12985-023-02167-z

Figure Lengend Snippet: Cohort flow chart. A Cohort of non-vaccinated SARS-CoV-2 RT-PCR positive subjects. Two recruitment strategies were used: fifty-one participants, who had a SARS CoV-2 infection in February/March 2020 were recruited in April 2020 together with their household members (KUM-Index-study). Forty-two of them had a positive PCR and additional 9 household members developed SARS CoV-2 specific antibodies. From 21 May till 10 December 2020 another fifty-one SARS-CoV-2 infected individuals were recruited as early as possible after their first positive RT-PCR (Koco19-Immu-Study). B Cohort of vaccinees. Forty-five participants with no history of infection but with two vaccinations were recruited

Article Snippet: For sample time-points of PCR-positive participants the following assays were performed: Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgA/IgG (hereafter called EI-S1-IgA/EI-S1-IgG; Euroimmun, Lübeck, Germany), Quantitative Euroimmun Anti-SARS-CoV-2-QuantiVac ELISA (IgG) (hereafter called EI-S1-IgG-quant; Euroimmun, Lübeck, Germany), Roche Elecsys Anti-SARS-CoV-2 anti-N and Elecsys Anti-SARS-CoV-2 S anti-S1 (hereafter called Ro-N-Ig and Ro-RBD-Ig-quant, respectively; Roche, Mannheim, Germany) and GenScript® (hereafter called GS-cPass, Piscataway, New Jersey, USA).

Techniques: Reverse Transcription Polymerase Chain Reaction, Infection

Longitudinal serological dynamics of SARS-CoV-2 RT-PCR positive cohort. Solid black horizontals line denote the cut-off for positivity. Blue lines represent the WHO reference panel for anti-SARS-CoV-2 immunoglobulin (NIBSC code 20/268). Each line represents one subject, the dots represent the individual samples. All assays were performed from the same sample in a head-to-head comparison. Top left: Euroimmun Anti Spike IgA; top right: Euroimmun Anti-Spike IgG; middle left: Roche Anti-Nucleocapsid; middle right: Roche Anti Spike/RBD; bottom: GenScript neutralization surrogate test

Journal: Virology Journal

Article Title: Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison

doi: 10.1186/s12985-023-02167-z

Figure Lengend Snippet: Longitudinal serological dynamics of SARS-CoV-2 RT-PCR positive cohort. Solid black horizontals line denote the cut-off for positivity. Blue lines represent the WHO reference panel for anti-SARS-CoV-2 immunoglobulin (NIBSC code 20/268). Each line represents one subject, the dots represent the individual samples. All assays were performed from the same sample in a head-to-head comparison. Top left: Euroimmun Anti Spike IgA; top right: Euroimmun Anti-Spike IgG; middle left: Roche Anti-Nucleocapsid; middle right: Roche Anti Spike/RBD; bottom: GenScript neutralization surrogate test

Article Snippet: For sample time-points of PCR-positive participants the following assays were performed: Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgA/IgG (hereafter called EI-S1-IgA/EI-S1-IgG; Euroimmun, Lübeck, Germany), Quantitative Euroimmun Anti-SARS-CoV-2-QuantiVac ELISA (IgG) (hereafter called EI-S1-IgG-quant; Euroimmun, Lübeck, Germany), Roche Elecsys Anti-SARS-CoV-2 anti-N and Elecsys Anti-SARS-CoV-2 S anti-S1 (hereafter called Ro-N-Ig and Ro-RBD-Ig-quant, respectively; Roche, Mannheim, Germany) and GenScript® (hereafter called GS-cPass, Piscataway, New Jersey, USA).

Techniques: Reverse Transcription Polymerase Chain Reaction, Comparison, Neutralization

Comparison of quantitative serology of individual patients (PCR-positive cohort) over time for EI-S1-IgG-quant-trafo and Ro-RBD-Ig-quant. When assays are compared, the EI-S1-IgG-quant-trafo is represented in blue while Ro-RBD-Ig-quant in yellow. Blue lines represent the WHO reference panel for anti-SARS-CoV-2 immunoglobulin (NIBSC code 20/268). Solid horizontal lines represent the cut-off for positivity. A Longitudinal EI-S1-IgG-quant-trafo serology data over time. Each line represents one subject, the dots represent the individual samples. The red solid line shows the LOESS (locally estimated scatterplot smoothing or local regression) estimations with CI in translucent red. B Aggregated BAU value curves of the subjects over time for the two tests. EI-S1-IgG-quant-trafo rises faster, reaches similar values than Ro-RBD-Ig-quant between days 70 and 150 after infection and then drops to about 1/10th of the value observed in Ro-RBD-Ig-quant after one year (please note that here almost half of the samples measured in EI-S1-IgG-quant-trafo are already below the positivity threshold). C Parallel coordinate plot dividing the time from symptom onset into three intervals: short (0–20 days), intermediate (70–150 days) and long (170–250 days). EI denotes the EI-S1-IgG-quant-trafo assay while Ro represents the Ro-RBD-Ig-quant assay. D The Quotient of the two BAU values depicted in log10 scale over time (Ro-RBD-Ig-quant/EI-S1-IgG-quant-trafo). At the Factor Value of 1, the BAU values are identical. This occurs only in a short timeframe about 80 days post symptom onset

Journal: Virology Journal

Article Title: Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison

doi: 10.1186/s12985-023-02167-z

Figure Lengend Snippet: Comparison of quantitative serology of individual patients (PCR-positive cohort) over time for EI-S1-IgG-quant-trafo and Ro-RBD-Ig-quant. When assays are compared, the EI-S1-IgG-quant-trafo is represented in blue while Ro-RBD-Ig-quant in yellow. Blue lines represent the WHO reference panel for anti-SARS-CoV-2 immunoglobulin (NIBSC code 20/268). Solid horizontal lines represent the cut-off for positivity. A Longitudinal EI-S1-IgG-quant-trafo serology data over time. Each line represents one subject, the dots represent the individual samples. The red solid line shows the LOESS (locally estimated scatterplot smoothing or local regression) estimations with CI in translucent red. B Aggregated BAU value curves of the subjects over time for the two tests. EI-S1-IgG-quant-trafo rises faster, reaches similar values than Ro-RBD-Ig-quant between days 70 and 150 after infection and then drops to about 1/10th of the value observed in Ro-RBD-Ig-quant after one year (please note that here almost half of the samples measured in EI-S1-IgG-quant-trafo are already below the positivity threshold). C Parallel coordinate plot dividing the time from symptom onset into three intervals: short (0–20 days), intermediate (70–150 days) and long (170–250 days). EI denotes the EI-S1-IgG-quant-trafo assay while Ro represents the Ro-RBD-Ig-quant assay. D The Quotient of the two BAU values depicted in log10 scale over time (Ro-RBD-Ig-quant/EI-S1-IgG-quant-trafo). At the Factor Value of 1, the BAU values are identical. This occurs only in a short timeframe about 80 days post symptom onset

Article Snippet: For sample time-points of PCR-positive participants the following assays were performed: Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgA/IgG (hereafter called EI-S1-IgA/EI-S1-IgG; Euroimmun, Lübeck, Germany), Quantitative Euroimmun Anti-SARS-CoV-2-QuantiVac ELISA (IgG) (hereafter called EI-S1-IgG-quant; Euroimmun, Lübeck, Germany), Roche Elecsys Anti-SARS-CoV-2 anti-N and Elecsys Anti-SARS-CoV-2 S anti-S1 (hereafter called Ro-N-Ig and Ro-RBD-Ig-quant, respectively; Roche, Mannheim, Germany) and GenScript® (hereafter called GS-cPass, Piscataway, New Jersey, USA).

Techniques: Comparison, Infection

Comparison of individual Anti-S1 BAU values of vaccinees over time for EI-S1-IgG-quant and Ro-RBD-Ig-quant, respectively. The time zero denotes the day of the second vaccination. The EI-S1-IgG-quant is represented in blue while Ro-RBD-Ig-quant in yellow. Solid horizontal lines represent the cut-off for positivity. A Longitudinal serology data of subjects over time. Each line represents one subject, the dots represent the individual samples. The solid lines show the LOESSs (locally estimated scatterplot smoothing or local regressions) estimations with CI as a shadowed region. The dashed black lines denotes 250 BUS/mL. B Parallel coordinate plot dividing the time from symptom onset into three intervals: short (0–20 days), intermediate (70–150 days) and long (170–250 days). EI denotes the EI-S1-IgG-quant assay while RO the Ro-RBD-Ig-quant assay. C Quotient of the two BAU values depicted in log10 scale over time (Ro-RBD-Ig-quant/EI-S1-IgG-quant-trafo); at 1, the BAU values are identical. Blue lines represent the WHO reference panel for anti-SARS-CoV-2 immunoglobulin (NIBSC code 20/268)

Journal: Virology Journal

Article Title: Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison

doi: 10.1186/s12985-023-02167-z

Figure Lengend Snippet: Comparison of individual Anti-S1 BAU values of vaccinees over time for EI-S1-IgG-quant and Ro-RBD-Ig-quant, respectively. The time zero denotes the day of the second vaccination. The EI-S1-IgG-quant is represented in blue while Ro-RBD-Ig-quant in yellow. Solid horizontal lines represent the cut-off for positivity. A Longitudinal serology data of subjects over time. Each line represents one subject, the dots represent the individual samples. The solid lines show the LOESSs (locally estimated scatterplot smoothing or local regressions) estimations with CI as a shadowed region. The dashed black lines denotes 250 BUS/mL. B Parallel coordinate plot dividing the time from symptom onset into three intervals: short (0–20 days), intermediate (70–150 days) and long (170–250 days). EI denotes the EI-S1-IgG-quant assay while RO the Ro-RBD-Ig-quant assay. C Quotient of the two BAU values depicted in log10 scale over time (Ro-RBD-Ig-quant/EI-S1-IgG-quant-trafo); at 1, the BAU values are identical. Blue lines represent the WHO reference panel for anti-SARS-CoV-2 immunoglobulin (NIBSC code 20/268)

Article Snippet: For sample time-points of PCR-positive participants the following assays were performed: Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgA/IgG (hereafter called EI-S1-IgA/EI-S1-IgG; Euroimmun, Lübeck, Germany), Quantitative Euroimmun Anti-SARS-CoV-2-QuantiVac ELISA (IgG) (hereafter called EI-S1-IgG-quant; Euroimmun, Lübeck, Germany), Roche Elecsys Anti-SARS-CoV-2 anti-N and Elecsys Anti-SARS-CoV-2 S anti-S1 (hereafter called Ro-N-Ig and Ro-RBD-Ig-quant, respectively; Roche, Mannheim, Germany) and GenScript® (hereafter called GS-cPass, Piscataway, New Jersey, USA).

Techniques: Comparison

Assay performance for SARS-CoV-2 antibody testing on dried blood spot specimens (DBS).

Journal: PLoS ONE

Article Title: Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison

doi: 10.1371/journal.pone.0261003

Figure Lengend Snippet: Assay performance for SARS-CoV-2 antibody testing on dried blood spot specimens (DBS).

Article Snippet: The commercial tests consisted of 6 IgG based assays: Anti-SARS-CoV-2 ELISA (EUROIMMUN), LIASON SARS-CoV-2 (DiaSorin, Saluggia, Italy), SARS-CoV-2 COV2G (Siemens, Erlangen, Germany), Architect SARS-CoV-2 (Abbott, Mississauga, Canada), and GSP/DELFIA Anti-SARS-CoV-2 (PerkinElmer, Waltham, Massachusetts); and 5 total antibody assays: Platelia SARS-CoV-2 (Bio-Rad), SARS-CoV-2 COV2T (Siemens), Elecsys quantitative Anti-SARS-CoV-2 (Elecsys spike; Roche, Basel, Switzerland), Elecsys Anti-SARS-CoV-2 (Elecsys nucleocapsid; Roche), and VITROS Anti-SARS-CoV-2 (Ortho Clinical Diagnostics, Raritan, New Jersey).

Techniques: Clinical Proteomics

Inter-assay concordance (A) and Cohen’s kappa coefficient (B) for SARS-CoV-2 antibody testing on dried blood spot specimens. Concordance (%) and Cohen’s kappa coefficient are presented for n = 10 SARS-CoV-2 antibody negative DBS specimens and n = 10 SARS-CoV-2 antibody positive DBS specimens. One 6 mm (1/4 inch) punch was used for the EUROIMMUN assay and two 6 mm (1/4 inch) punches were used for the Platelia and in-house assays. EUROIMMUN = Anti-SARS-CoV-2 ELISA assay (EUROIMMUN, Lübeck, Germany). Platelia = SARS-CoV-2 assay (Bio-Rad, Hercules, California). LIASON = SARS-CoV-2 assay (DiaSorin, Saluggia, Italy). COV2G = SARS-CoV-2 COV2G assay (Siemens, Erlangen, Germany). COV2T = SARS-CoV-2 COV2T assay (Siemens). Elecsys S = Quantitative Anti-SARS-CoV-2 assay (Elecsys spike; Roche, Basel, Switzerland). Elecsys N = Anti-SARS-CoV-2 assay (Elecsys nucleocapsid; Roche). VITROS = Anti-SARS-CoV-2 assay (Ortho Clinical Diagnostics, Raritan, New Jersey). Architect = SARS-CoV-2 assay (Abbott, Mississauga, Canada). GSP/DELFIA = Anti-SARS-CoV-2 assay (PerkinElmer, Waltham, Massachusetts). In-house S (U of T) = In-house spike assay (University of Toronto). In-house RBD (U of T) = In-house RBD assay (University of Toronto). In-house N (U of T) = In-house nucleocapsid assay (University of Toronto). In-house S, mono (U of O) = In- house monoclonal spike assay (University of Ottawa). In-house RBD, mono (U of O) = In-house monoclonal RBD assay (University of Ottawa). In-house N, mono (U of O) = In-house monoclonal nucleocapsid assay (University of Ottawa).

Journal: PLoS ONE

Article Title: Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison

doi: 10.1371/journal.pone.0261003

Figure Lengend Snippet: Inter-assay concordance (A) and Cohen’s kappa coefficient (B) for SARS-CoV-2 antibody testing on dried blood spot specimens. Concordance (%) and Cohen’s kappa coefficient are presented for n = 10 SARS-CoV-2 antibody negative DBS specimens and n = 10 SARS-CoV-2 antibody positive DBS specimens. One 6 mm (1/4 inch) punch was used for the EUROIMMUN assay and two 6 mm (1/4 inch) punches were used for the Platelia and in-house assays. EUROIMMUN = Anti-SARS-CoV-2 ELISA assay (EUROIMMUN, Lübeck, Germany). Platelia = SARS-CoV-2 assay (Bio-Rad, Hercules, California). LIASON = SARS-CoV-2 assay (DiaSorin, Saluggia, Italy). COV2G = SARS-CoV-2 COV2G assay (Siemens, Erlangen, Germany). COV2T = SARS-CoV-2 COV2T assay (Siemens). Elecsys S = Quantitative Anti-SARS-CoV-2 assay (Elecsys spike; Roche, Basel, Switzerland). Elecsys N = Anti-SARS-CoV-2 assay (Elecsys nucleocapsid; Roche). VITROS = Anti-SARS-CoV-2 assay (Ortho Clinical Diagnostics, Raritan, New Jersey). Architect = SARS-CoV-2 assay (Abbott, Mississauga, Canada). GSP/DELFIA = Anti-SARS-CoV-2 assay (PerkinElmer, Waltham, Massachusetts). In-house S (U of T) = In-house spike assay (University of Toronto). In-house RBD (U of T) = In-house RBD assay (University of Toronto). In-house N (U of T) = In-house nucleocapsid assay (University of Toronto). In-house S, mono (U of O) = In- house monoclonal spike assay (University of Ottawa). In-house RBD, mono (U of O) = In-house monoclonal RBD assay (University of Ottawa). In-house N, mono (U of O) = In-house monoclonal nucleocapsid assay (University of Ottawa).

Article Snippet: The commercial tests consisted of 6 IgG based assays: Anti-SARS-CoV-2 ELISA (EUROIMMUN), LIASON SARS-CoV-2 (DiaSorin, Saluggia, Italy), SARS-CoV-2 COV2G (Siemens, Erlangen, Germany), Architect SARS-CoV-2 (Abbott, Mississauga, Canada), and GSP/DELFIA Anti-SARS-CoV-2 (PerkinElmer, Waltham, Massachusetts); and 5 total antibody assays: Platelia SARS-CoV-2 (Bio-Rad), SARS-CoV-2 COV2T (Siemens), Elecsys quantitative Anti-SARS-CoV-2 (Elecsys spike; Roche, Basel, Switzerland), Elecsys Anti-SARS-CoV-2 (Elecsys nucleocapsid; Roche), and VITROS Anti-SARS-CoV-2 (Ortho Clinical Diagnostics, Raritan, New Jersey).

Techniques: Inter Assay, Clinical Proteomics, Enzyme-linked Immunosorbent Assay

PPV and NPV is presented for n = 10 SARS-CoV-2 antibody negative DBS specimens and n = 10 SARS-CoV-2 antibody positive DBS specimens. One 6 mm (1/4 inch) punch was used for the EUROIMMUN assay and two 6 mm (1/4 inch) punches were used for the Platelia and in-house assays. Data from four 6 mm (1/4 inch) punches is presented for all other assays. EUROIMMUN = Anti-SARS-CoV-2 ELISA assay (EUROIMMUN, Lübeck, Germany). Platelia = SARS-CoV-2 assay (Bio-Rad, Hercules, California). LIASON = SARS-CoV-2 assay (DiaSorin, Saluggia, Italy). COV2G = SARS-CoV-2 COV2G assay (Siemens, Erlangen, Germany). COV2T = SARS-CoV-2 COV2T assay (Siemens). Elecsys S = Quantitative Anti-SARS-CoV-2 assay (Elecsys spike; Roche, Basel, Switzerland). Elecsys N = Anti-SARS-CoV-2 assay (Elecsys nucleocapsid; Roche). VITROS = Anti-SARS-CoV-2 assay (Ortho Clinical Diagnostics, Raritan, New Jersey). Architect = SARS-CoV-2 assay (Abbott, Mississauga, Canada). GSP/DELFIA = Anti-SARS-CoV-2 assay (PerkinElmer, Waltham, Massachusetts). In-house S (U of T) = In-house spike assay (University of Toronto). In-house RBD (U of T) = In-house RBD assay (University of Toronto). In-house N (U of T) = In-house nucleocapsid assay (University of Toronto). In-house S, mono (U of O) = In-house monoclonal spike assay (University of Ottawa). In-house RBD, mono (U of O) = In-house monoclonal RBD assay (University of Ottawa). In-house N, mono (U of O) = In-house monoclonal nucleocapsid assay (University of Ottawa). The VITROS assay could not achieve a specificity greater than 0% therefore, only PPV is shown.

Journal: PLoS ONE

Article Title: Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison

doi: 10.1371/journal.pone.0261003

Figure Lengend Snippet: PPV and NPV is presented for n = 10 SARS-CoV-2 antibody negative DBS specimens and n = 10 SARS-CoV-2 antibody positive DBS specimens. One 6 mm (1/4 inch) punch was used for the EUROIMMUN assay and two 6 mm (1/4 inch) punches were used for the Platelia and in-house assays. Data from four 6 mm (1/4 inch) punches is presented for all other assays. EUROIMMUN = Anti-SARS-CoV-2 ELISA assay (EUROIMMUN, Lübeck, Germany). Platelia = SARS-CoV-2 assay (Bio-Rad, Hercules, California). LIASON = SARS-CoV-2 assay (DiaSorin, Saluggia, Italy). COV2G = SARS-CoV-2 COV2G assay (Siemens, Erlangen, Germany). COV2T = SARS-CoV-2 COV2T assay (Siemens). Elecsys S = Quantitative Anti-SARS-CoV-2 assay (Elecsys spike; Roche, Basel, Switzerland). Elecsys N = Anti-SARS-CoV-2 assay (Elecsys nucleocapsid; Roche). VITROS = Anti-SARS-CoV-2 assay (Ortho Clinical Diagnostics, Raritan, New Jersey). Architect = SARS-CoV-2 assay (Abbott, Mississauga, Canada). GSP/DELFIA = Anti-SARS-CoV-2 assay (PerkinElmer, Waltham, Massachusetts). In-house S (U of T) = In-house spike assay (University of Toronto). In-house RBD (U of T) = In-house RBD assay (University of Toronto). In-house N (U of T) = In-house nucleocapsid assay (University of Toronto). In-house S, mono (U of O) = In-house monoclonal spike assay (University of Ottawa). In-house RBD, mono (U of O) = In-house monoclonal RBD assay (University of Ottawa). In-house N, mono (U of O) = In-house monoclonal nucleocapsid assay (University of Ottawa). The VITROS assay could not achieve a specificity greater than 0% therefore, only PPV is shown.

Article Snippet: The commercial tests consisted of 6 IgG based assays: Anti-SARS-CoV-2 ELISA (EUROIMMUN), LIASON SARS-CoV-2 (DiaSorin, Saluggia, Italy), SARS-CoV-2 COV2G (Siemens, Erlangen, Germany), Architect SARS-CoV-2 (Abbott, Mississauga, Canada), and GSP/DELFIA Anti-SARS-CoV-2 (PerkinElmer, Waltham, Massachusetts); and 5 total antibody assays: Platelia SARS-CoV-2 (Bio-Rad), SARS-CoV-2 COV2T (Siemens), Elecsys quantitative Anti-SARS-CoV-2 (Elecsys spike; Roche, Basel, Switzerland), Elecsys Anti-SARS-CoV-2 (Elecsys nucleocapsid; Roche), and VITROS Anti-SARS-CoV-2 (Ortho Clinical Diagnostics, Raritan, New Jersey).

Techniques: Enzyme-linked Immunosorbent Assay

ROC curves are presented for n = 10 SARS-CoV-2 antibody negative DBS specimens and n = 10 SARS-CoV-2 antibody positive DBS specimens. One 6 mm (1/4 inch) punch was used for the EUROIMMUN assay and two 6 mm (1/4 inch) punches were used for the Platelia and in-house assays. Data from four 6 mm (1/4 inch) punches is presented for all other assays. EUROIMMUN = Anti-SARS-CoV-2 ELISA assay (EUROIMMUN, Lübeck, Germany). Platelia = SARS-CoV-2 assay (Bio-Rad, Hercules, California). LIASON = SARS-CoV-2 assay (DiaSorin, Saluggia, Italy). COV2G = SARS-CoV-2 COV2G assay (Siemens, Erlangen, Germany). COV2T = SARS-CoV-2 COV2T assay (Siemens). Elecsys S = Quantitative Anti-SARS-CoV-2 assay (Elecsys spike; Roche, Basel, Switzerland). Elecsys N = Anti-SARS-CoV-2 assay (Elecsys nucleocapsid; Roche). VITROS = Anti-SARS-CoV-2 assay (Ortho Clinical Diagnostics, Raritan, New Jersey). Architect = SARS-CoV-2 assay (Abbott, Mississauga, Canada). GSP/DELFIA = Anti-SARS-CoV-2 assay (PerkinElmer, Waltham, Massachusetts). In-house S (U of T) = In-house spike assay (University of Toronto). In-house RBD (U of T) = In-house RBD assay (University of Toronto). In-house N (U of T) = In-house nucleocapsid assay (University of Toronto). In-house S, mono (U of O) = In-house monoclonal spike assay (University of Ottawa). In-house RBD, mono (U of O) = In-house monoclonal RBD assay (University of Ottawa). In-house N, mono (U of O) = In-house monoclonal nucleocapsid assay (University of Ottawa).

Journal: PLoS ONE

Article Title: Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison

doi: 10.1371/journal.pone.0261003

Figure Lengend Snippet: ROC curves are presented for n = 10 SARS-CoV-2 antibody negative DBS specimens and n = 10 SARS-CoV-2 antibody positive DBS specimens. One 6 mm (1/4 inch) punch was used for the EUROIMMUN assay and two 6 mm (1/4 inch) punches were used for the Platelia and in-house assays. Data from four 6 mm (1/4 inch) punches is presented for all other assays. EUROIMMUN = Anti-SARS-CoV-2 ELISA assay (EUROIMMUN, Lübeck, Germany). Platelia = SARS-CoV-2 assay (Bio-Rad, Hercules, California). LIASON = SARS-CoV-2 assay (DiaSorin, Saluggia, Italy). COV2G = SARS-CoV-2 COV2G assay (Siemens, Erlangen, Germany). COV2T = SARS-CoV-2 COV2T assay (Siemens). Elecsys S = Quantitative Anti-SARS-CoV-2 assay (Elecsys spike; Roche, Basel, Switzerland). Elecsys N = Anti-SARS-CoV-2 assay (Elecsys nucleocapsid; Roche). VITROS = Anti-SARS-CoV-2 assay (Ortho Clinical Diagnostics, Raritan, New Jersey). Architect = SARS-CoV-2 assay (Abbott, Mississauga, Canada). GSP/DELFIA = Anti-SARS-CoV-2 assay (PerkinElmer, Waltham, Massachusetts). In-house S (U of T) = In-house spike assay (University of Toronto). In-house RBD (U of T) = In-house RBD assay (University of Toronto). In-house N (U of T) = In-house nucleocapsid assay (University of Toronto). In-house S, mono (U of O) = In-house monoclonal spike assay (University of Ottawa). In-house RBD, mono (U of O) = In-house monoclonal RBD assay (University of Ottawa). In-house N, mono (U of O) = In-house monoclonal nucleocapsid assay (University of Ottawa).

Article Snippet: The commercial tests consisted of 6 IgG based assays: Anti-SARS-CoV-2 ELISA (EUROIMMUN), LIASON SARS-CoV-2 (DiaSorin, Saluggia, Italy), SARS-CoV-2 COV2G (Siemens, Erlangen, Germany), Architect SARS-CoV-2 (Abbott, Mississauga, Canada), and GSP/DELFIA Anti-SARS-CoV-2 (PerkinElmer, Waltham, Massachusetts); and 5 total antibody assays: Platelia SARS-CoV-2 (Bio-Rad), SARS-CoV-2 COV2T (Siemens), Elecsys quantitative Anti-SARS-CoV-2 (Elecsys spike; Roche, Basel, Switzerland), Elecsys Anti-SARS-CoV-2 (Elecsys nucleocapsid; Roche), and VITROS Anti-SARS-CoV-2 (Ortho Clinical Diagnostics, Raritan, New Jersey).

Techniques: Enzyme-linked Immunosorbent Assay

Each panel shows the optical density ratio (OD Ratio), arbitrary units per mL (AU/mL), index, units per mL (U/mL), cut-off index, or signal to cut-off ratio (S/Co) for SARS-CoV-2 antibody negative DBS specimens (n = 10) represented in blue and SARS-CoV-2 antibody positive DBS specimens (n = 10) represented in orange. All values are log 10 transformed to aid with visualisation. One 6 mm (1/4 inch) punch was used for the EUROIMMUN assay and two 6 mm (1/4 inch) punches were used for the Platelia and in-house assays. Data from four 6 mm (1/4 inch) punches is presented for all other assays. EUROIMMUN = Anti-SARS-CoV-2 ELISA assay (EUROIMMUN, Lübeck, Germany). Platelia = SARS-CoV-2 assay (Bio-Rad, Hercules, California). LIASON = SARS-CoV-2 assay (DiaSorin, Saluggia, Italy). COV2G = SARS-CoV-2 COV2G assay (Siemens, Erlangen, Germany). COV2T = SARS-CoV-2 COV2T assay (Siemens). Elecsys S = Quantitative Anti-SARS-CoV-2 assay (Elecsys spike; Roche, Basel, Switzerland). Elecsys N = Anti-SARS-CoV-2 assay (Elecsys nucleocapsid; Roche). VITROS = Anti-SARS-CoV-2 assay (Ortho Clinical Diagnostics, Raritan, New Jersey). Architect = SARS-CoV-2 assay (Abbott, Mississauga, Canada). GSP/DELFIA = Anti-SARS-CoV-2 assay (PerkinElmer, Waltham, Massachusetts). In-house S (U of T) = In-house spike assay (University of Toronto). In-house RBD (U of T) = In-house RBD assay (University of Toronto). In-house N (U of T) = In-house nucleocapsid assay (University of Toronto). In-house S, mono (U of O) = In-house monoclonal spike assay (University of Ottawa). In-house RBD, mono (U of O) = In-house monoclonal RBD assay (University of Ottawa). In-house N, mono (U of O) = In-house monoclonal nucleocapsid assay (University of Ottawa).

Journal: PLoS ONE

Article Title: Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison

doi: 10.1371/journal.pone.0261003

Figure Lengend Snippet: Each panel shows the optical density ratio (OD Ratio), arbitrary units per mL (AU/mL), index, units per mL (U/mL), cut-off index, or signal to cut-off ratio (S/Co) for SARS-CoV-2 antibody negative DBS specimens (n = 10) represented in blue and SARS-CoV-2 antibody positive DBS specimens (n = 10) represented in orange. All values are log 10 transformed to aid with visualisation. One 6 mm (1/4 inch) punch was used for the EUROIMMUN assay and two 6 mm (1/4 inch) punches were used for the Platelia and in-house assays. Data from four 6 mm (1/4 inch) punches is presented for all other assays. EUROIMMUN = Anti-SARS-CoV-2 ELISA assay (EUROIMMUN, Lübeck, Germany). Platelia = SARS-CoV-2 assay (Bio-Rad, Hercules, California). LIASON = SARS-CoV-2 assay (DiaSorin, Saluggia, Italy). COV2G = SARS-CoV-2 COV2G assay (Siemens, Erlangen, Germany). COV2T = SARS-CoV-2 COV2T assay (Siemens). Elecsys S = Quantitative Anti-SARS-CoV-2 assay (Elecsys spike; Roche, Basel, Switzerland). Elecsys N = Anti-SARS-CoV-2 assay (Elecsys nucleocapsid; Roche). VITROS = Anti-SARS-CoV-2 assay (Ortho Clinical Diagnostics, Raritan, New Jersey). Architect = SARS-CoV-2 assay (Abbott, Mississauga, Canada). GSP/DELFIA = Anti-SARS-CoV-2 assay (PerkinElmer, Waltham, Massachusetts). In-house S (U of T) = In-house spike assay (University of Toronto). In-house RBD (U of T) = In-house RBD assay (University of Toronto). In-house N (U of T) = In-house nucleocapsid assay (University of Toronto). In-house S, mono (U of O) = In-house monoclonal spike assay (University of Ottawa). In-house RBD, mono (U of O) = In-house monoclonal RBD assay (University of Ottawa). In-house N, mono (U of O) = In-house monoclonal nucleocapsid assay (University of Ottawa).

Article Snippet: The commercial tests consisted of 6 IgG based assays: Anti-SARS-CoV-2 ELISA (EUROIMMUN), LIASON SARS-CoV-2 (DiaSorin, Saluggia, Italy), SARS-CoV-2 COV2G (Siemens, Erlangen, Germany), Architect SARS-CoV-2 (Abbott, Mississauga, Canada), and GSP/DELFIA Anti-SARS-CoV-2 (PerkinElmer, Waltham, Massachusetts); and 5 total antibody assays: Platelia SARS-CoV-2 (Bio-Rad), SARS-CoV-2 COV2T (Siemens), Elecsys quantitative Anti-SARS-CoV-2 (Elecsys spike; Roche, Basel, Switzerland), Elecsys Anti-SARS-CoV-2 (Elecsys nucleocapsid; Roche), and VITROS Anti-SARS-CoV-2 (Ortho Clinical Diagnostics, Raritan, New Jersey).

Techniques: Transformation Assay, Enzyme-linked Immunosorbent Assay

Area under the receiver operating characteristic curve (AUC) for each commercial and in-house assay on dried blood spot specimens (DBS).

Journal: PLoS ONE

Article Title: Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison

doi: 10.1371/journal.pone.0261003

Figure Lengend Snippet: Area under the receiver operating characteristic curve (AUC) for each commercial and in-house assay on dried blood spot specimens (DBS).

Article Snippet: The commercial tests consisted of 6 IgG based assays: Anti-SARS-CoV-2 ELISA (EUROIMMUN), LIASON SARS-CoV-2 (DiaSorin, Saluggia, Italy), SARS-CoV-2 COV2G (Siemens, Erlangen, Germany), Architect SARS-CoV-2 (Abbott, Mississauga, Canada), and GSP/DELFIA Anti-SARS-CoV-2 (PerkinElmer, Waltham, Massachusetts); and 5 total antibody assays: Platelia SARS-CoV-2 (Bio-Rad), SARS-CoV-2 COV2T (Siemens), Elecsys quantitative Anti-SARS-CoV-2 (Elecsys spike; Roche, Basel, Switzerland), Elecsys Anti-SARS-CoV-2 (Elecsys nucleocapsid; Roche), and VITROS Anti-SARS-CoV-2 (Ortho Clinical Diagnostics, Raritan, New Jersey).

Techniques: Clinical Proteomics

Commercial and in-house serological tests assessed for SARS-CoV-2 antibody testing on dried blood spot specimens.

Journal: PLoS ONE

Article Title: Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison

doi: 10.1371/journal.pone.0261003

Figure Lengend Snippet: Commercial and in-house serological tests assessed for SARS-CoV-2 antibody testing on dried blood spot specimens.

Article Snippet: The commercial tests consisted of 6 IgG based assays: Anti-SARS-CoV-2 ELISA (EUROIMMUN), LIASON SARS-CoV-2 (DiaSorin, Saluggia, Italy), SARS-CoV-2 COV2G (Siemens, Erlangen, Germany), Architect SARS-CoV-2 (Abbott, Mississauga, Canada), and GSP/DELFIA Anti-SARS-CoV-2 (PerkinElmer, Waltham, Massachusetts); and 5 total antibody assays: Platelia SARS-CoV-2 (Bio-Rad), SARS-CoV-2 COV2T (Siemens), Elecsys quantitative Anti-SARS-CoV-2 (Elecsys spike; Roche, Basel, Switzerland), Elecsys Anti-SARS-CoV-2 (Elecsys nucleocapsid; Roche), and VITROS Anti-SARS-CoV-2 (Ortho Clinical Diagnostics, Raritan, New Jersey).

Techniques: Clinical Proteomics, Enzyme-linked Immunosorbent Assay

Assay performance for SARS-CoV-2 antibody testing on dried blood spot specimens (DBS).

Journal: PLoS ONE

Article Title: Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison

doi: 10.1371/journal.pone.0261003

Figure Lengend Snippet: Assay performance for SARS-CoV-2 antibody testing on dried blood spot specimens (DBS).

Article Snippet: The commercial tests consisted of 6 IgG based assays: Anti-SARS-CoV-2 ELISA (EUROIMMUN), LIASON SARS-CoV-2 (DiaSorin, Saluggia, Italy), SARS-CoV-2 COV2G (Siemens, Erlangen, Germany), Architect SARS-CoV-2 (Abbott, Mississauga, Canada), and GSP/DELFIA Anti-SARS-CoV-2 (PerkinElmer, Waltham, Massachusetts); and 5 total antibody assays: Platelia SARS-CoV-2 (Bio-Rad), SARS-CoV-2 COV2T (Siemens), Elecsys quantitative Anti-SARS-CoV-2 (Elecsys spike; Roche, Basel, Switzerland), Elecsys Anti-SARS-CoV-2 (Elecsys nucleocapsid; Roche), and VITROS Anti-SARS-CoV-2 (Ortho Clinical Diagnostics, Raritan, New Jersey).

Techniques: Clinical Proteomics

Inter-assay concordance (A) and Cohen’s kappa coefficient (B) for SARS-CoV-2 antibody testing on dried blood spot specimens. Concordance (%) and Cohen’s kappa coefficient are presented for n = 10 SARS-CoV-2 antibody negative DBS specimens and n = 10 SARS-CoV-2 antibody positive DBS specimens. One 6 mm (1/4 inch) punch was used for the EUROIMMUN assay and two 6 mm (1/4 inch) punches were used for the Platelia and in-house assays. EUROIMMUN = Anti-SARS-CoV-2 ELISA assay (EUROIMMUN, Lübeck, Germany). Platelia = SARS-CoV-2 assay (Bio-Rad, Hercules, California). LIASON = SARS-CoV-2 assay (DiaSorin, Saluggia, Italy). COV2G = SARS-CoV-2 COV2G assay (Siemens, Erlangen, Germany). COV2T = SARS-CoV-2 COV2T assay (Siemens). Elecsys S = Quantitative Anti-SARS-CoV-2 assay (Elecsys spike; Roche, Basel, Switzerland). Elecsys N = Anti-SARS-CoV-2 assay (Elecsys nucleocapsid; Roche). VITROS = Anti-SARS-CoV-2 assay (Ortho Clinical Diagnostics, Raritan, New Jersey). Architect = SARS-CoV-2 assay (Abbott, Mississauga, Canada). GSP/DELFIA = Anti-SARS-CoV-2 assay (PerkinElmer, Waltham, Massachusetts). In-house S (U of T) = In-house spike assay (University of Toronto). In-house RBD (U of T) = In-house RBD assay (University of Toronto). In-house N (U of T) = In-house nucleocapsid assay (University of Toronto). In-house S, mono (U of O) = In- house monoclonal spike assay (University of Ottawa). In-house RBD, mono (U of O) = In-house monoclonal RBD assay (University of Ottawa). In-house N, mono (U of O) = In-house monoclonal nucleocapsid assay (University of Ottawa).

Journal: PLoS ONE

Article Title: Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison

doi: 10.1371/journal.pone.0261003

Figure Lengend Snippet: Inter-assay concordance (A) and Cohen’s kappa coefficient (B) for SARS-CoV-2 antibody testing on dried blood spot specimens. Concordance (%) and Cohen’s kappa coefficient are presented for n = 10 SARS-CoV-2 antibody negative DBS specimens and n = 10 SARS-CoV-2 antibody positive DBS specimens. One 6 mm (1/4 inch) punch was used for the EUROIMMUN assay and two 6 mm (1/4 inch) punches were used for the Platelia and in-house assays. EUROIMMUN = Anti-SARS-CoV-2 ELISA assay (EUROIMMUN, Lübeck, Germany). Platelia = SARS-CoV-2 assay (Bio-Rad, Hercules, California). LIASON = SARS-CoV-2 assay (DiaSorin, Saluggia, Italy). COV2G = SARS-CoV-2 COV2G assay (Siemens, Erlangen, Germany). COV2T = SARS-CoV-2 COV2T assay (Siemens). Elecsys S = Quantitative Anti-SARS-CoV-2 assay (Elecsys spike; Roche, Basel, Switzerland). Elecsys N = Anti-SARS-CoV-2 assay (Elecsys nucleocapsid; Roche). VITROS = Anti-SARS-CoV-2 assay (Ortho Clinical Diagnostics, Raritan, New Jersey). Architect = SARS-CoV-2 assay (Abbott, Mississauga, Canada). GSP/DELFIA = Anti-SARS-CoV-2 assay (PerkinElmer, Waltham, Massachusetts). In-house S (U of T) = In-house spike assay (University of Toronto). In-house RBD (U of T) = In-house RBD assay (University of Toronto). In-house N (U of T) = In-house nucleocapsid assay (University of Toronto). In-house S, mono (U of O) = In- house monoclonal spike assay (University of Ottawa). In-house RBD, mono (U of O) = In-house monoclonal RBD assay (University of Ottawa). In-house N, mono (U of O) = In-house monoclonal nucleocapsid assay (University of Ottawa).

Article Snippet: The commercial tests consisted of 6 IgG based assays: Anti-SARS-CoV-2 ELISA (EUROIMMUN), LIASON SARS-CoV-2 (DiaSorin, Saluggia, Italy), SARS-CoV-2 COV2G (Siemens, Erlangen, Germany), Architect SARS-CoV-2 (Abbott, Mississauga, Canada), and GSP/DELFIA Anti-SARS-CoV-2 (PerkinElmer, Waltham, Massachusetts); and 5 total antibody assays: Platelia SARS-CoV-2 (Bio-Rad), SARS-CoV-2 COV2T (Siemens), Elecsys quantitative Anti-SARS-CoV-2 (Elecsys spike; Roche, Basel, Switzerland), Elecsys Anti-SARS-CoV-2 (Elecsys nucleocapsid; Roche), and VITROS Anti-SARS-CoV-2 (Ortho Clinical Diagnostics, Raritan, New Jersey).

Techniques: Inter Assay, Clinical Proteomics, Enzyme-linked Immunosorbent Assay

PPV and NPV is presented for n = 10 SARS-CoV-2 antibody negative DBS specimens and n = 10 SARS-CoV-2 antibody positive DBS specimens. One 6 mm (1/4 inch) punch was used for the EUROIMMUN assay and two 6 mm (1/4 inch) punches were used for the Platelia and in-house assays. Data from four 6 mm (1/4 inch) punches is presented for all other assays. EUROIMMUN = Anti-SARS-CoV-2 ELISA assay (EUROIMMUN, Lübeck, Germany). Platelia = SARS-CoV-2 assay (Bio-Rad, Hercules, California). LIASON = SARS-CoV-2 assay (DiaSorin, Saluggia, Italy). COV2G = SARS-CoV-2 COV2G assay (Siemens, Erlangen, Germany). COV2T = SARS-CoV-2 COV2T assay (Siemens). Elecsys S = Quantitative Anti-SARS-CoV-2 assay (Elecsys spike; Roche, Basel, Switzerland). Elecsys N = Anti-SARS-CoV-2 assay (Elecsys nucleocapsid; Roche). VITROS = Anti-SARS-CoV-2 assay (Ortho Clinical Diagnostics, Raritan, New Jersey). Architect = SARS-CoV-2 assay (Abbott, Mississauga, Canada). GSP/DELFIA = Anti-SARS-CoV-2 assay (PerkinElmer, Waltham, Massachusetts). In-house S (U of T) = In-house spike assay (University of Toronto). In-house RBD (U of T) = In-house RBD assay (University of Toronto). In-house N (U of T) = In-house nucleocapsid assay (University of Toronto). In-house S, mono (U of O) = In-house monoclonal spike assay (University of Ottawa). In-house RBD, mono (U of O) = In-house monoclonal RBD assay (University of Ottawa). In-house N, mono (U of O) = In-house monoclonal nucleocapsid assay (University of Ottawa). The VITROS assay could not achieve a specificity greater than 0% therefore, only PPV is shown.

Journal: PLoS ONE

Article Title: Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison

doi: 10.1371/journal.pone.0261003

Figure Lengend Snippet: PPV and NPV is presented for n = 10 SARS-CoV-2 antibody negative DBS specimens and n = 10 SARS-CoV-2 antibody positive DBS specimens. One 6 mm (1/4 inch) punch was used for the EUROIMMUN assay and two 6 mm (1/4 inch) punches were used for the Platelia and in-house assays. Data from four 6 mm (1/4 inch) punches is presented for all other assays. EUROIMMUN = Anti-SARS-CoV-2 ELISA assay (EUROIMMUN, Lübeck, Germany). Platelia = SARS-CoV-2 assay (Bio-Rad, Hercules, California). LIASON = SARS-CoV-2 assay (DiaSorin, Saluggia, Italy). COV2G = SARS-CoV-2 COV2G assay (Siemens, Erlangen, Germany). COV2T = SARS-CoV-2 COV2T assay (Siemens). Elecsys S = Quantitative Anti-SARS-CoV-2 assay (Elecsys spike; Roche, Basel, Switzerland). Elecsys N = Anti-SARS-CoV-2 assay (Elecsys nucleocapsid; Roche). VITROS = Anti-SARS-CoV-2 assay (Ortho Clinical Diagnostics, Raritan, New Jersey). Architect = SARS-CoV-2 assay (Abbott, Mississauga, Canada). GSP/DELFIA = Anti-SARS-CoV-2 assay (PerkinElmer, Waltham, Massachusetts). In-house S (U of T) = In-house spike assay (University of Toronto). In-house RBD (U of T) = In-house RBD assay (University of Toronto). In-house N (U of T) = In-house nucleocapsid assay (University of Toronto). In-house S, mono (U of O) = In-house monoclonal spike assay (University of Ottawa). In-house RBD, mono (U of O) = In-house monoclonal RBD assay (University of Ottawa). In-house N, mono (U of O) = In-house monoclonal nucleocapsid assay (University of Ottawa). The VITROS assay could not achieve a specificity greater than 0% therefore, only PPV is shown.

Article Snippet: The commercial tests consisted of 6 IgG based assays: Anti-SARS-CoV-2 ELISA (EUROIMMUN), LIASON SARS-CoV-2 (DiaSorin, Saluggia, Italy), SARS-CoV-2 COV2G (Siemens, Erlangen, Germany), Architect SARS-CoV-2 (Abbott, Mississauga, Canada), and GSP/DELFIA Anti-SARS-CoV-2 (PerkinElmer, Waltham, Massachusetts); and 5 total antibody assays: Platelia SARS-CoV-2 (Bio-Rad), SARS-CoV-2 COV2T (Siemens), Elecsys quantitative Anti-SARS-CoV-2 (Elecsys spike; Roche, Basel, Switzerland), Elecsys Anti-SARS-CoV-2 (Elecsys nucleocapsid; Roche), and VITROS Anti-SARS-CoV-2 (Ortho Clinical Diagnostics, Raritan, New Jersey).

Techniques: Enzyme-linked Immunosorbent Assay

ROC curves are presented for n = 10 SARS-CoV-2 antibody negative DBS specimens and n = 10 SARS-CoV-2 antibody positive DBS specimens. One 6 mm (1/4 inch) punch was used for the EUROIMMUN assay and two 6 mm (1/4 inch) punches were used for the Platelia and in-house assays. Data from four 6 mm (1/4 inch) punches is presented for all other assays. EUROIMMUN = Anti-SARS-CoV-2 ELISA assay (EUROIMMUN, Lübeck, Germany). Platelia = SARS-CoV-2 assay (Bio-Rad, Hercules, California). LIASON = SARS-CoV-2 assay (DiaSorin, Saluggia, Italy). COV2G = SARS-CoV-2 COV2G assay (Siemens, Erlangen, Germany). COV2T = SARS-CoV-2 COV2T assay (Siemens). Elecsys S = Quantitative Anti-SARS-CoV-2 assay (Elecsys spike; Roche, Basel, Switzerland). Elecsys N = Anti-SARS-CoV-2 assay (Elecsys nucleocapsid; Roche). VITROS = Anti-SARS-CoV-2 assay (Ortho Clinical Diagnostics, Raritan, New Jersey). Architect = SARS-CoV-2 assay (Abbott, Mississauga, Canada). GSP/DELFIA = Anti-SARS-CoV-2 assay (PerkinElmer, Waltham, Massachusetts). In-house S (U of T) = In-house spike assay (University of Toronto). In-house RBD (U of T) = In-house RBD assay (University of Toronto). In-house N (U of T) = In-house nucleocapsid assay (University of Toronto). In-house S, mono (U of O) = In-house monoclonal spike assay (University of Ottawa). In-house RBD, mono (U of O) = In-house monoclonal RBD assay (University of Ottawa). In-house N, mono (U of O) = In-house monoclonal nucleocapsid assay (University of Ottawa).

Journal: PLoS ONE

Article Title: Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison

doi: 10.1371/journal.pone.0261003

Figure Lengend Snippet: ROC curves are presented for n = 10 SARS-CoV-2 antibody negative DBS specimens and n = 10 SARS-CoV-2 antibody positive DBS specimens. One 6 mm (1/4 inch) punch was used for the EUROIMMUN assay and two 6 mm (1/4 inch) punches were used for the Platelia and in-house assays. Data from four 6 mm (1/4 inch) punches is presented for all other assays. EUROIMMUN = Anti-SARS-CoV-2 ELISA assay (EUROIMMUN, Lübeck, Germany). Platelia = SARS-CoV-2 assay (Bio-Rad, Hercules, California). LIASON = SARS-CoV-2 assay (DiaSorin, Saluggia, Italy). COV2G = SARS-CoV-2 COV2G assay (Siemens, Erlangen, Germany). COV2T = SARS-CoV-2 COV2T assay (Siemens). Elecsys S = Quantitative Anti-SARS-CoV-2 assay (Elecsys spike; Roche, Basel, Switzerland). Elecsys N = Anti-SARS-CoV-2 assay (Elecsys nucleocapsid; Roche). VITROS = Anti-SARS-CoV-2 assay (Ortho Clinical Diagnostics, Raritan, New Jersey). Architect = SARS-CoV-2 assay (Abbott, Mississauga, Canada). GSP/DELFIA = Anti-SARS-CoV-2 assay (PerkinElmer, Waltham, Massachusetts). In-house S (U of T) = In-house spike assay (University of Toronto). In-house RBD (U of T) = In-house RBD assay (University of Toronto). In-house N (U of T) = In-house nucleocapsid assay (University of Toronto). In-house S, mono (U of O) = In-house monoclonal spike assay (University of Ottawa). In-house RBD, mono (U of O) = In-house monoclonal RBD assay (University of Ottawa). In-house N, mono (U of O) = In-house monoclonal nucleocapsid assay (University of Ottawa).

Article Snippet: The commercial tests consisted of 6 IgG based assays: Anti-SARS-CoV-2 ELISA (EUROIMMUN), LIASON SARS-CoV-2 (DiaSorin, Saluggia, Italy), SARS-CoV-2 COV2G (Siemens, Erlangen, Germany), Architect SARS-CoV-2 (Abbott, Mississauga, Canada), and GSP/DELFIA Anti-SARS-CoV-2 (PerkinElmer, Waltham, Massachusetts); and 5 total antibody assays: Platelia SARS-CoV-2 (Bio-Rad), SARS-CoV-2 COV2T (Siemens), Elecsys quantitative Anti-SARS-CoV-2 (Elecsys spike; Roche, Basel, Switzerland), Elecsys Anti-SARS-CoV-2 (Elecsys nucleocapsid; Roche), and VITROS Anti-SARS-CoV-2 (Ortho Clinical Diagnostics, Raritan, New Jersey).

Techniques: Enzyme-linked Immunosorbent Assay

Each panel shows the optical density ratio (OD Ratio), arbitrary units per mL (AU/mL), index, units per mL (U/mL), cut-off index, or signal to cut-off ratio (S/Co) for SARS-CoV-2 antibody negative DBS specimens (n = 10) represented in blue and SARS-CoV-2 antibody positive DBS specimens (n = 10) represented in orange. All values are log 10 transformed to aid with visualisation. One 6 mm (1/4 inch) punch was used for the EUROIMMUN assay and two 6 mm (1/4 inch) punches were used for the Platelia and in-house assays. Data from four 6 mm (1/4 inch) punches is presented for all other assays. EUROIMMUN = Anti-SARS-CoV-2 ELISA assay (EUROIMMUN, Lübeck, Germany). Platelia = SARS-CoV-2 assay (Bio-Rad, Hercules, California). LIASON = SARS-CoV-2 assay (DiaSorin, Saluggia, Italy). COV2G = SARS-CoV-2 COV2G assay (Siemens, Erlangen, Germany). COV2T = SARS-CoV-2 COV2T assay (Siemens). Elecsys S = Quantitative Anti-SARS-CoV-2 assay (Elecsys spike; Roche, Basel, Switzerland). Elecsys N = Anti-SARS-CoV-2 assay (Elecsys nucleocapsid; Roche). VITROS = Anti-SARS-CoV-2 assay (Ortho Clinical Diagnostics, Raritan, New Jersey). Architect = SARS-CoV-2 assay (Abbott, Mississauga, Canada). GSP/DELFIA = Anti-SARS-CoV-2 assay (PerkinElmer, Waltham, Massachusetts). In-house S (U of T) = In-house spike assay (University of Toronto). In-house RBD (U of T) = In-house RBD assay (University of Toronto). In-house N (U of T) = In-house nucleocapsid assay (University of Toronto). In-house S, mono (U of O) = In-house monoclonal spike assay (University of Ottawa). In-house RBD, mono (U of O) = In-house monoclonal RBD assay (University of Ottawa). In-house N, mono (U of O) = In-house monoclonal nucleocapsid assay (University of Ottawa).

Journal: PLoS ONE

Article Title: Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison

doi: 10.1371/journal.pone.0261003

Figure Lengend Snippet: Each panel shows the optical density ratio (OD Ratio), arbitrary units per mL (AU/mL), index, units per mL (U/mL), cut-off index, or signal to cut-off ratio (S/Co) for SARS-CoV-2 antibody negative DBS specimens (n = 10) represented in blue and SARS-CoV-2 antibody positive DBS specimens (n = 10) represented in orange. All values are log 10 transformed to aid with visualisation. One 6 mm (1/4 inch) punch was used for the EUROIMMUN assay and two 6 mm (1/4 inch) punches were used for the Platelia and in-house assays. Data from four 6 mm (1/4 inch) punches is presented for all other assays. EUROIMMUN = Anti-SARS-CoV-2 ELISA assay (EUROIMMUN, Lübeck, Germany). Platelia = SARS-CoV-2 assay (Bio-Rad, Hercules, California). LIASON = SARS-CoV-2 assay (DiaSorin, Saluggia, Italy). COV2G = SARS-CoV-2 COV2G assay (Siemens, Erlangen, Germany). COV2T = SARS-CoV-2 COV2T assay (Siemens). Elecsys S = Quantitative Anti-SARS-CoV-2 assay (Elecsys spike; Roche, Basel, Switzerland). Elecsys N = Anti-SARS-CoV-2 assay (Elecsys nucleocapsid; Roche). VITROS = Anti-SARS-CoV-2 assay (Ortho Clinical Diagnostics, Raritan, New Jersey). Architect = SARS-CoV-2 assay (Abbott, Mississauga, Canada). GSP/DELFIA = Anti-SARS-CoV-2 assay (PerkinElmer, Waltham, Massachusetts). In-house S (U of T) = In-house spike assay (University of Toronto). In-house RBD (U of T) = In-house RBD assay (University of Toronto). In-house N (U of T) = In-house nucleocapsid assay (University of Toronto). In-house S, mono (U of O) = In-house monoclonal spike assay (University of Ottawa). In-house RBD, mono (U of O) = In-house monoclonal RBD assay (University of Ottawa). In-house N, mono (U of O) = In-house monoclonal nucleocapsid assay (University of Ottawa).

Article Snippet: The commercial tests consisted of 6 IgG based assays: Anti-SARS-CoV-2 ELISA (EUROIMMUN), LIASON SARS-CoV-2 (DiaSorin, Saluggia, Italy), SARS-CoV-2 COV2G (Siemens, Erlangen, Germany), Architect SARS-CoV-2 (Abbott, Mississauga, Canada), and GSP/DELFIA Anti-SARS-CoV-2 (PerkinElmer, Waltham, Massachusetts); and 5 total antibody assays: Platelia SARS-CoV-2 (Bio-Rad), SARS-CoV-2 COV2T (Siemens), Elecsys quantitative Anti-SARS-CoV-2 (Elecsys spike; Roche, Basel, Switzerland), Elecsys Anti-SARS-CoV-2 (Elecsys nucleocapsid; Roche), and VITROS Anti-SARS-CoV-2 (Ortho Clinical Diagnostics, Raritan, New Jersey).

Techniques: Transformation Assay, Enzyme-linked Immunosorbent Assay

Area under the receiver operating characteristic curve (AUC) for each commercial and in-house assay on dried blood spot specimens (DBS).

Journal: PLoS ONE

Article Title: Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison

doi: 10.1371/journal.pone.0261003

Figure Lengend Snippet: Area under the receiver operating characteristic curve (AUC) for each commercial and in-house assay on dried blood spot specimens (DBS).

Article Snippet: The commercial tests consisted of 6 IgG based assays: Anti-SARS-CoV-2 ELISA (EUROIMMUN), LIASON SARS-CoV-2 (DiaSorin, Saluggia, Italy), SARS-CoV-2 COV2G (Siemens, Erlangen, Germany), Architect SARS-CoV-2 (Abbott, Mississauga, Canada), and GSP/DELFIA Anti-SARS-CoV-2 (PerkinElmer, Waltham, Massachusetts); and 5 total antibody assays: Platelia SARS-CoV-2 (Bio-Rad), SARS-CoV-2 COV2T (Siemens), Elecsys quantitative Anti-SARS-CoV-2 (Elecsys spike; Roche, Basel, Switzerland), Elecsys Anti-SARS-CoV-2 (Elecsys nucleocapsid; Roche), and VITROS Anti-SARS-CoV-2 (Ortho Clinical Diagnostics, Raritan, New Jersey).

Techniques: Clinical Proteomics

Commercial and in-house serological tests assessed for SARS-CoV-2 antibody testing on dried blood spot specimens.

Journal: PLoS ONE

Article Title: Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison

doi: 10.1371/journal.pone.0261003

Figure Lengend Snippet: Commercial and in-house serological tests assessed for SARS-CoV-2 antibody testing on dried blood spot specimens.

Article Snippet: The commercial tests consisted of 6 IgG based assays: Anti-SARS-CoV-2 ELISA (EUROIMMUN), LIASON SARS-CoV-2 (DiaSorin, Saluggia, Italy), SARS-CoV-2 COV2G (Siemens, Erlangen, Germany), Architect SARS-CoV-2 (Abbott, Mississauga, Canada), and GSP/DELFIA Anti-SARS-CoV-2 (PerkinElmer, Waltham, Massachusetts); and 5 total antibody assays: Platelia SARS-CoV-2 (Bio-Rad), SARS-CoV-2 COV2T (Siemens), Elecsys quantitative Anti-SARS-CoV-2 (Elecsys spike; Roche, Basel, Switzerland), Elecsys Anti-SARS-CoV-2 (Elecsys nucleocapsid; Roche), and VITROS Anti-SARS-CoV-2 (Ortho Clinical Diagnostics, Raritan, New Jersey).

Techniques: Clinical Proteomics, Enzyme-linked Immunosorbent Assay